Source link : https://newshealth.biz/health-news/evidence-mounts-for-darolutamide-plus-adt-in-hormone-sensitive-prostate-cancer/
WASHINGTON — Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), the phase II ARASEC trial showed. In the study, which used an external control arm from the historic CHAARTED trial, median progression-free survival (PFS) was not estimable with the combination of […]
The post Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-18 19:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8